Drug and Drug candidate building block analysis

Junmei Wang, Tingjun Hou

Research output: Contribution to journalArticle

59 Citations (Scopus)

Abstract

Drug likeness analysis is widely used in modem drug design, However, most drug likeness filters, represented by Lipinski's "Rule of 5", are based on drugs' simple structural features and some physiochemical properties. In this study, we conducted thorough structural analyses for two drug datasets. The first dataset, ADDS, is composed of 1240 FDA-approved drugs, and the second drug dataset, EDDS, is a nonredundant collection of FDA-approved drugs and experimental drugs in different phases of clinical trials from several drug databases (6932 entries). For each molecule, all possible fragments were enumerated using a brutal force approach. Three kinds of building blocks, namely, the drug scaffold, ring system, and the small fragment, were identified and ranked according to the frequencies of their occurrence in drug molecules. The major finding is that most top fragments are essentially common for both drug datasets; the top 50 fragments cover 52.6% and 48.6% drugs for ADDS and EDDS, respectively. The identified building blocks were further ranked according to their relative hit rates in the drug datasets and in a screening dataset, which is a nonredundant collection of screening compounds from many resources. In comparison with the previous reports in the field, we have identified many more high-quality building blocks. The results obtained in this study could provide useful hints to medicinal chemists in designing drug-like compounds as well as prioritizing screening libraries to filter out those molecules lack of functional building blocks.

Original languageEnglish (US)
Pages (from-to)55-67
Number of pages13
JournalJournal of Chemical Information and Modeling
Volume50
Issue number1
DOIs
StatePublished - Jan 25 2010

Fingerprint

Screening
candidacy
drug
Molecules
Pharmaceutical Preparations
Modems
Scaffolds
chemist

ASJC Scopus subject areas

  • Chemistry(all)
  • Chemical Engineering(all)
  • Computer Science Applications
  • Library and Information Sciences

Cite this

Drug and Drug candidate building block analysis. / Wang, Junmei; Hou, Tingjun.

In: Journal of Chemical Information and Modeling, Vol. 50, No. 1, 25.01.2010, p. 55-67.

Research output: Contribution to journalArticle

@article{5ef0477e460e447b99288a39167e45f4,
title = "Drug and Drug candidate building block analysis",
abstract = "Drug likeness analysis is widely used in modem drug design, However, most drug likeness filters, represented by Lipinski's {"}Rule of 5{"}, are based on drugs' simple structural features and some physiochemical properties. In this study, we conducted thorough structural analyses for two drug datasets. The first dataset, ADDS, is composed of 1240 FDA-approved drugs, and the second drug dataset, EDDS, is a nonredundant collection of FDA-approved drugs and experimental drugs in different phases of clinical trials from several drug databases (6932 entries). For each molecule, all possible fragments were enumerated using a brutal force approach. Three kinds of building blocks, namely, the drug scaffold, ring system, and the small fragment, were identified and ranked according to the frequencies of their occurrence in drug molecules. The major finding is that most top fragments are essentially common for both drug datasets; the top 50 fragments cover 52.6{\%} and 48.6{\%} drugs for ADDS and EDDS, respectively. The identified building blocks were further ranked according to their relative hit rates in the drug datasets and in a screening dataset, which is a nonredundant collection of screening compounds from many resources. In comparison with the previous reports in the field, we have identified many more high-quality building blocks. The results obtained in this study could provide useful hints to medicinal chemists in designing drug-like compounds as well as prioritizing screening libraries to filter out those molecules lack of functional building blocks.",
author = "Junmei Wang and Tingjun Hou",
year = "2010",
month = "1",
day = "25",
doi = "10.1021/ci900398f",
language = "English (US)",
volume = "50",
pages = "55--67",
journal = "Journal of Chemical Information and Modeling",
issn = "1549-9596",
publisher = "American Chemical Society",
number = "1",

}

TY - JOUR

T1 - Drug and Drug candidate building block analysis

AU - Wang, Junmei

AU - Hou, Tingjun

PY - 2010/1/25

Y1 - 2010/1/25

N2 - Drug likeness analysis is widely used in modem drug design, However, most drug likeness filters, represented by Lipinski's "Rule of 5", are based on drugs' simple structural features and some physiochemical properties. In this study, we conducted thorough structural analyses for two drug datasets. The first dataset, ADDS, is composed of 1240 FDA-approved drugs, and the second drug dataset, EDDS, is a nonredundant collection of FDA-approved drugs and experimental drugs in different phases of clinical trials from several drug databases (6932 entries). For each molecule, all possible fragments were enumerated using a brutal force approach. Three kinds of building blocks, namely, the drug scaffold, ring system, and the small fragment, were identified and ranked according to the frequencies of their occurrence in drug molecules. The major finding is that most top fragments are essentially common for both drug datasets; the top 50 fragments cover 52.6% and 48.6% drugs for ADDS and EDDS, respectively. The identified building blocks were further ranked according to their relative hit rates in the drug datasets and in a screening dataset, which is a nonredundant collection of screening compounds from many resources. In comparison with the previous reports in the field, we have identified many more high-quality building blocks. The results obtained in this study could provide useful hints to medicinal chemists in designing drug-like compounds as well as prioritizing screening libraries to filter out those molecules lack of functional building blocks.

AB - Drug likeness analysis is widely used in modem drug design, However, most drug likeness filters, represented by Lipinski's "Rule of 5", are based on drugs' simple structural features and some physiochemical properties. In this study, we conducted thorough structural analyses for two drug datasets. The first dataset, ADDS, is composed of 1240 FDA-approved drugs, and the second drug dataset, EDDS, is a nonredundant collection of FDA-approved drugs and experimental drugs in different phases of clinical trials from several drug databases (6932 entries). For each molecule, all possible fragments were enumerated using a brutal force approach. Three kinds of building blocks, namely, the drug scaffold, ring system, and the small fragment, were identified and ranked according to the frequencies of their occurrence in drug molecules. The major finding is that most top fragments are essentially common for both drug datasets; the top 50 fragments cover 52.6% and 48.6% drugs for ADDS and EDDS, respectively. The identified building blocks were further ranked according to their relative hit rates in the drug datasets and in a screening dataset, which is a nonredundant collection of screening compounds from many resources. In comparison with the previous reports in the field, we have identified many more high-quality building blocks. The results obtained in this study could provide useful hints to medicinal chemists in designing drug-like compounds as well as prioritizing screening libraries to filter out those molecules lack of functional building blocks.

UR - http://www.scopus.com/inward/record.url?scp=75749105013&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=75749105013&partnerID=8YFLogxK

U2 - 10.1021/ci900398f

DO - 10.1021/ci900398f

M3 - Article

C2 - 20020714

AN - SCOPUS:75749105013

VL - 50

SP - 55

EP - 67

JO - Journal of Chemical Information and Modeling

JF - Journal of Chemical Information and Modeling

SN - 1549-9596

IS - 1

ER -